The aim o� this article is to discuss the protocol o� betablockers that is commonly used �or prospectively ECGtriggered coronary computed tomography angiography (CCTA). It is essential to ensure a low and regular heart rate in patients undergoing prospectively ECG-triggered CCTA �or optimal visualization o� coronary arteries. Although early generations o� computed tomographyscanners are not applicable to be tailored according to patients' heart rate, a low and regular heart rate is possible to be achieved by the administration o� medications according to the beta-blocker protocol. Betablocker can be sa�ely administered to reduce patients' heart rate �or CCTA examination i� patients are screened �or certain contraindications.
INTRODUCTION
Prospectively ECG-triggered coronary computed tomography angiography (CCTA) is increasingly used in the diagnosis of coronary artery disease (CAD) due to its very low radiation dose with acceptable image quality [1] [2] [3] . This technique not only provides comparable diagnostic accuracy to that of conventional approach, retrospectively ECG-gated CCTA, but also shows superior advantage in reducing radiation dose (up to 83%), which is significantly lower than that from retrospectively ECG-gated protocol [1] [2] [3] [4] . However, in order to ensure that image quality is acceptable for clinical diagnosis, prospectively ECG-triggered CCTA is restricted to patients with low (heart rates less than 65 bpm) and regular (HR variability < ± 5 bpm) during the scan [1, 2, 5] . With the advancements of computed tomography (CT) technology, the latest generation of multislice CT scanners enables customization of the scanning protocol to tailor individual patient's condition such as using multiple heartbeat scanning modes or application of additional padding windows [5, 6] . Thus, the prospectively ECG-triggered CCTA Zhonghua Sun, Associate Professor, Series Editor Sabarudin A et al . Beta-blocker administration protocol could be extended to more patients with variable heart rates. However, these protocols suffer from radiation dose which limits the widespread use of the prospectively ECGtriggering technique in cardiac imaging. Therefore, the use of beta-blockers is an option which is widely used in CCTA studies to reduce the heart rate to less than 65-70 bpm and to make the cardiac rhythm more regular [7] . All of the beta-blockers used in clinical practice are competitive pharmacologic antagonists. Drugs in betablocker group can be classified into subgroups on the basis of β1 selectivity, partial agonist activity, local anesthetic action and lipid solubility (Table 1) [7, 8] . Most of the organ-level effects of beta-blockers are predictable blockade of the beta-receptor-mediated effects of sympathetic discharge. The clinical applications of beta-blockade are broad ranging from treating glaucoma to cardiovascular disease [8] .
The applications of beta-blockers in cardiovascular disease treatment are of paramount importance, especially in the situations such as hypertension, angina and arrhythmias [8] . However, adverse cardiovascular effects such as bradycardia, atrioventricular blockade and heart failure may occur due to beta-blockade toxicity. Patient with airway disease may suffer severe asthma attacks. In addition, adverse effects of central nervous system include sedation, fatigue and sleep alterations might only occur with use of lipid soluble beta-blockers. Sexual dysfunction has been reported in some patients using the beta blockers [8, 9] . It has been shown in clinical studies that Beta-blocking agents have a preferential effect on beta1 adrenoreceptors, mainly located in the cardiac muscle [8, 10, 11] . Beta-blockers lessen cardiac contractility and heart rates by blocking myocardial beta-receptors, and therefore prevent exerciseinduced increase in oxygen demands by the heart [9] . Clinical pharmacology studies have confirmed that betablocking activity had enormous effect on the reduction in heart rate and cardiac output at rest and upon exercise, reduction of systolic blood pressure upon exercise, reduction of reflex orthostatic tachycardia and inhibition of isoproterenol-induced tachycardia [8, 10, 11] . Therefore, betablockers are recommended to be administered prior to CCTA scanning. The purpose of this article is to provide an overview of the use of beta-blockers administration protocol for prospectively ECG-triggered CCTA.
PATIENT PREPARATION
There are several common indications for prospectively ECG-triggered CCTA inclusive of the CAD indications and non-CAD indications. CAD indications are inclusive of evaluation of coronary arteries in patients with newonset heart failure to assess etiology, symptomatic patients at intermediate preset probability of CAD, patients with a chest pain syndrome regardless of acute or chronic with interpretable stress test. In certain circumstances, CCTA is required although non-CAD detection indications are presented such as suspected pulmonary embolism or aortic dissection or aneurysm, assessment of complex congenital heart disease, suspected coronary anomalies in symptomatic patients, evaluation of pulmonary vein anatomy prior to atrial fibrillation radiofrequency ablation, evaluation of cardiac venous anatomy prior to biventricular pacing and evaluation of cardiac mass or pericardial condition when non-radiation imaging modalities are limited [12, 13] . However, there are some contraindications to CCTA procedure which include pregnancy, severe anaphylactic contrast reaction, unable to comply with the scanning instructions such as fail to hold long breath-hold, renal insufficiency and clinically unstable patients [12, 13] . In addition, identification to contraindicated drug must be clarified before undergoing CCTA procedure inclusive of the prescan nitroglycerine such as severe aortic stenosis, hypertrophic cardiomyopathy and phosphodiesterase-5 (PDE-5) inhibitor and beta-blockers [8, 12] . For patients who are considered to undergo beta-blocker protocol, some guidelines have been suggested to avoid complications including screening contraindications to beta-blockers [7] . The contraindications include sinus bradycardia, which is defined as a heart rate of < 60 bpm with systolic pressure of less than 100 mmHg; allergic to beta-adrenergic antagonists or its constituents; decompensated cardiac failure; asthma on beta-agonist inhalers; active bronchospasm; second or third-degree of atrioventricular (AV) block [14] [15] [16] . Patients who are likely to have second-or third-degree AV block can be evaluated by generating a single-lead ECG strip [7] . Patient's vital signs and pulse are also monitored and documented upon arrival. In patients with a sinus rhythm with heart rate < 65 bpm, no beta-blockers are required and therefore, the patient can be prepared for CCTA ex- amination. In patients with irregular rhythm or/and higher heart rate (> 65 bpm), the beta-blockers are given according to the protocol setting ( Figure 1 ). In addition, patients are required to follow all standard instructions for contrast-enhanced studies including fasting for at least 4 h prior to the scan, maintaining oral hydration with clear fluid up to 1 h before scan and need to hold metformin for a minimum of 48 h following the scan. Patients with non-severe anaphylactic contrast reaction in the past should receive pre-medication treatment to avoid the risk of current contrast reaction. A premedication protocol suggested as 50 mg of prednisone is administered orally 13, 7 and 1 h prior to scan with additional of 50 mg oral diphenhydramine (Benadryl) is taken 1 h prior to scan [12, 17] . With regards to optimal heart rate control, caffeine product is not permitted within 12 h of CCTA. Moreover, severe hypotension can occur if PDE-5 inhibitors interact with nitrates. Therefore, patients are refrained from undertaking PDE-5 inhibitor drugs such as sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) for at least 48 h before CCTA [12, 18, 19] . However, usual cardiovascular medications are advisable to be taken continuously.
ADMINISTRATION OF BETA-BLOCKERS AND OTHER ALTERNATIVE DRUG IN HEART RATE-LOWERING THERAPY
Several cardio selective beta-blockers are available with distinct pharmacokinetic profiles such as acebutolol hydrochloride, atenolol, betaxolol hydrochloride, bisoprolol, esmolol, metoprolol succinate and metoprolol tartrate. However, metoprolol tartrate (Lopressor) was selected due to its convenient method of administration, dosage form availability and cardioselectivity [7] . Unlike oral metoprolol tartrate, intravenous metoprolol dosage form is recommended due to its fast onset reaction (between 5 and 10 min) after administration. On the other hand, metoprolol tablets (oral) effect can only be seen within 1 hour after administration and the peak plasma concentrations are seen at 90 min. Although the onset reaction in both oral and Ⅳ routes differ significantly, the plasma half-life for metoprolol tartrate is similar in both oral and Ⅳ which ranges from 3 to 4 h in a healthy adult [7, 15, 16] . Oral pre-medication in heart rate-lowering therapy is another alternative to achieve lower heart rate prior to the CT scanning. Pre-medicating the patient with tablet metoprolol gives an advantage which may reduce the risk of being injected with Ⅳ of metoprolol. However, without proper scanning arrangement, the effect of the oral metoprolol might not be effective and other factors such as anxiety and nervousness may also increase the patients' heart rate on the day of the examination. Thus, administration of metoprolol intravenously is most commonly performed prior to the CT scanning due to its fast onset and clinically feasibility.
Most previous practices injected their first bolus of metoprolol once the patient is lying down supine on the CT examination table. Our practice suggests that first bolus administration of metoprolol (2.5 mg) is given before the patient is brought on the CT examination table; right after the Ⅳ line is set (pre-procedure). Then, the patient's heart rate is monitored at the designated area under supervision of medically authorized personnel. This aims to avoid interruption of the procedure workflow and the delay time for beta-blockers to respond.
Although beta-blockers helped in lowering the heart rate, they also have negative inotropic effect and could decrease left ventricular contractility which may affect the assessment of ventricular function [7] . However, ventricular function is only being evaluated by echocardiography or nuclear medicine studies and CCTA study is mainly performed for assessment of coronary arteries and degree of stenosis. Initially, two 2.5 mg doses of metoprolol are given with 5 min interval. Then two doses of 5 mg each are given 5 min apart with a total maximum dose of no more than 15 mg. Blood pressure and HR are monitored before each of the Ⅳ dose as stated in Figure 1 . The betablockers' administration is conducted under the supervision of the radiologists or cardiologists. Blood pressure and continuous ECG monitoring should always be used when giving Ⅳ metoprolol.
Ivabradine is another attractive option to reduce patient heart rate for CCTA procedure [20] . Unlike metoprolol, ivabradine selectively inhibits if current in sinoatrial node cells that controls the spontaneous diastolic depolarization, resulting in the reduction of diastolic depolarization rate and heart rate [21, 22] . Therefore, it is useful in patients in sinus rhythm, but not in other rhythms such as atrial fibrillation. Ivabradine lowers heart rate at concentrations that do not affect other cardiac ionic currents. Therefore, ivabradine has no other direct cardiovascular effect [20] . Therefore, the main pharmacodynamics of ivabradine in humans is a specific dose-dependent reduction in heart rate. Heart rate reduction is achieved approximately 10 beats/min (bpm) at rest and during exercise at the recommended dosage (no more than 10 mg/d) which leads to a reduction in cardiac workload and myocardial oxygen consumption [21] . Ivabradine has a relatively short half-life of around 2 h and is currently only available as an oral preparation.
HEART RATE CONTROL-LESS COMMONLY APPLIED IN 64-AND POST-64 CT
Heart rate control with use of medications is necessary in 4-and 16-slice CT, but less common in 64-and post-64 slice coronary CT angiography due to improvement in temporal resolution. Pache et al [23] in their early study showed that 64-slice CT has high diagnostic accuracy in the assessment of coronary artery bypass grafts, despite the presence of irregular or high heart rates. Recent tech-nological developments with the introduction of dualsource CT and 320-slice CT have overcome the limitation of early generation of multislice CT as the temporal resolution was significantly increased, thus image quality and diagnostic value of coronary CT angiography was less dependent on heart rates [24, 25] . It has been reported that dual-source coronary CT angiography shows improved diagnostic performance in patients with a wide range of different heart rates being included [26, 27] . Expansion of multislice CT systems from a prototype 256-slice to a 320-slice system has allowed for acquisition of whole heart coverage in one gantry rotation. Studies have shown that 320-slice coronary CT angiography demonstrated high sensitivity and specificity at per-patient, pervessel and per-segment analysis in patients with atrial fibrillation [28] [29] [30] . These results indicate that 320-slice CT has the potential to broaden the use of coronary CT angiography to more patients with high or irregular heart rates or those without responding well to the heart rate control.
POST-PROCEDURE CARE
All patients who are given Ⅳ metoprolol are observed for about 30 min once the scan is completed. If the patient presents with bronchospasm, an albuterol inhaler is given accordingly [7, 31] . If the patient's heart rate drops to less than 45 bpm, administration of atropine is considered. However, if the patient is resistant to the atropine while the heart rate drops continuously, resuscitative measures and Ⅳ administration of beta-agonists need to be administered such as dopamine or epinephrine [7] . In general, beta-blockers are helpful in patients with irregular heart rate, either with premature atrial or ventricular contractions, supraventricular tachycardia and arrhythmias such as arterial fibrillation. With atrial fibrillation, the negative chronotropic and dromotropic effects of the beta-blockers lengthen the diastolic portion of the No cardiac cycle [7, 8] . In prospectively ECG-triggered CCTA, X-ray exposure occurs during a small portion of the cardiac cycle typically centered at mid-diastole at 75% of R-R interval [1, 6] . Therefore, increasing diastole by beta-blockers would improve CCTA image quality. Previous studies showed that the vessel visibility was achieved with the single-segment reconstruction in patients with low heart rates (< 65 bpm) and with multisegment reconstructions in patients with high heart rates (> 65 bpm) [32, 33] . Moreover, the visibility of right coronary artery also has been shown to improve significantly with the administration of beta-blockers. The proportion of the cardiac cycle spent in diastole increases as the heart rate decreases. Therefore, use of beta-blockers is suggested to increase the diastolic phase in the cardiac cycle [34] .
In conclusion, beta-blockers administration protocol has been discussed in this article with regard to is usefulness in preparing patient's heart rate for prospectively ECG-triggered CCTA. Since use of medication is essential to ensure that coronary CT angiography will provide excellent diagnostic images with few artifacts, understanding the mechanism of beta-blockers in cardiac imaging will contribute to the efficient use of coronary CT angiography technique in clinical diagnosis. 
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